THAIS LARRÉ OLIVEIRA BOHN

Dr. THAIS LARRÉ OLIVEIRA BOHN


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
DCDomitila Brzoskowski Chagas
Domitila Brzoskowski Chagas
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
NONatasha Rodrigues de Oliveira
Natasha Rodrigues de Oliveira
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN
ODOdir Dellagostin
Odir Dellagostin
Vaccination is essential for maintaining animal health, with priority placed on safety and cost effectiveness in veterinary use. The development of recombinant live-attenuated Salmonella vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens. This review summarizes the progress made in this field, with a focus on clinical trials demonstrating the efficacy and commercial potential of RASVs in veterinary medicine.

19 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ODOdir Dellagostin
Odir Dellagostin
SBSibele Borsuk
Sibele Borsuk
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN
FSFabiana Kömmling Seixas
Fabiana Kömmling Seixas
Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other pathogens. However, BCG vaccination has limited efficacy in protecting against adult forms of tuberculosis (TB), raises concerns about its safety in immunocompromised populations, compromises the diagnosis of TB through the tuberculin test and lacks predictability for successful antigen expression and immune responses to heterologous antigens. Together, these factors propelled the construction and evaluation of auxotrophic BCG strains. Auxotrophs of BCG have been developed from mutations in the genes required for their growth using different approaches and have shown the potential to provide a model to study M. tuberculosis, a more stable, safe, and effective alternative to BCG and a vector for the development of recombinant live vaccines, especially against HIV infection. In this review, we provide an overview of the strategies for developing and using the auxotrophic BCG strains in different scenarios.

1 December 2019 in Tuberculosis
Verified
Journal Article
Closed access
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN
ASAnna Stedman
Anna Stedman
CRCaroline Rizzi
Caroline Rizzi
JDJessica Dorneles
Jessica Dorneles
CCCarlos Eduardo Pouey da Cunha
Carlos Eduardo Pouey da Cunha
JMJohnjoe Mcfadden
Johnjoe Mcfadden

4 October 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
TBTiffany Thurow Bunde
Tiffany Thurow Bunde
NONatasha Rodrigues de Oliveira
Natasha Rodrigues de Oliveira
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
APAna Carolina Kurz Pedra
Ana Carolina Kurz Pedra
MMMara Maia
Mara Maia
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN

26 September 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
TBTiffany T. Bunde
Tiffany T. Bunde
APAna C. K. Pedra
Ana C. K. Pedra
NONatasha R. de Oliveira
Natasha R. de Oliveira
ODOdir A. Dellagostin
Odir A. Dellagostin
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN

28 April 2026 in Molecular Biology Reports
Verified
Journal Article
Open access
PDF file
AMAndriele Bonemann Madruga
Andriele Bonemann Madruga
JNJady Duarte Nogueira
Jady Duarte Nogueira
MMMara Andrade Colares Maia
Mara Andrade Colares Maia
NONatasha Rodrigues de Oliveira
Natasha Rodrigues de Oliveira
MEMaria Eduarda Ehlert
Maria Eduarda Ehlert
TBTHAIS LARRÉ OLIVEIRA BOHN
THAIS LARRÉ OLIVEIRA BOHN
Background: Mycobacterium bovis BCG is widely used as a vaccine vector due to its safety, genetic stability, and immunomodulatory properties. However, current expression systems for BCG transformation rely on antibiotic resistance genes, raising biosafety concerns. Therefore, alternative strategies—such as the use of auxotrophic strains—are highly desirable. Our group previously employed BioBrick™ technology to construct the pUP500 plasmid series containing various mycobacterial promoters. We engineered these plasmids for the auxotrophic complementation of BCG ΔLeuD, a leucine-auxotrophic strain, using an antibiotic-free and BioBrick™-compatible approach. Methods and Results: The auxotrophic complementation cassette pAN- leuD was cloned into pUP500 plasmids. Subsequently, the egfp gene was inserted downstream of the promoters, the kanamycin resistance gene was removed, and fluorescence was assessed by flow cytometry, qPCR and confocal microscopy in BCG grown in 7H9 medium and inside macrophages. Auxotrophic complementation was confirmed by growth of transformants in non-selective medium and analysis of leuD expression, and plasmid stability was evaluated along six BCG generations. Strains harboring plasmids containing the pAN and HspX promoters exhibited stronger fluorescence levels both in vitro and within macrophages. In contrast, the 18 kDa promoter demonstrated marked activation specifically in the intracellular environment, driving robust gene expression inside macrophages. These expression patterns were significantly higher compared to strains carrying the Ag85B or Hsp60 promoters, as well as to the negative control. Except for the Hsp60 construct, all plasmids exhibited robust in vitro stability across six consecutive passages, supporting their potential as reliable expression systems for heterologous antigens in therapeutic and vaccine applications. Conclusions: We developed five BioBrick™-compatible plasmids with distinct promoters for auxotrophic complementation and antigen expression in BCG ΔLeuD, eliminating the need for antibiotic-based selection. This standardized plasmid series reduces vector-related variability in comparative studies and provides a diverse promoter repertoire that may enhance the stability and efficacy of recombinant BCG ΔLeuD strains, representing a valuable advancement for prophylactic and therapeutic vaccine development.